OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ORGC58

OrganoClick AB

Specialty ChemicalsVerified

OrganoClick's capital structure is highly leveraged, with a debt-to-equity ratio of 5.12, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.45 and negative free cash flow of -30.29 million SEK. The company's cash and equivalents of 2.68 million SEK are insufficient to cover its long-term debt of 77.78 million SEK, raising concerns about its ability to meet long-term obligations. Profitability metrics are deeply negative, with a return on equity of -239.63% and a return on assets of -26.9%. These figures are well below the typical performance of the specialty chemicals industry, which generally expects positive returns on invested capital. The company reported a net loss of 36.37 million SEK and an operating loss of 31.57 million SEK, indicating a failure to generate sustainable earnings. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks and limits the company's ability to offset losses in one area with gains in another. Growth prospects are uncertain, with the company reporting a revenue of 106.19 million SEK in the latest period. Analysts have estimated a modest increase to 113.00 million SEK, but the company's operating and net losses suggest that any growth is not yet translating into profitability. The negative operating cash flow of -8.29 million SEK and free cash flow of -30.29 million SEK further indicate that the company is not generating sufficient cash to sustain operations or fund growth. The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with the company's net cash position being negative after subtracting total debt. The dilution risk is rated as low, but the company's negative earnings and cash flow may necessitate future equity raises, which could dilute existing shareholders. Recent financial filings and transcripts indicate that the company is operating in a challenging market environment. The company's negative earnings and cash flow, combined with high debt levels, suggest that it is under pressure to improve its financial performance. No recent major events or strategic announcements have been disclosed that would indicate a clear path to profitability or growth.

30-day price · ORGC(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyOrganoClick AB
TickerORGC.ST
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. OrganoClick AB is a specialty chemicals company that develops and commercializes click chemistry reagents and building blocks for pharmaceutical and biotechnology applications.

Classification. OrganoClick is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with a confidence level of 0.92.

OrganoClick's capital structure is highly leveraged, with a debt-to-equity ratio of 5.12, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.45 and negative free cash flow of -30.29 million SEK. The company's cash and equivalents of 2.68 million SEK are insufficient to cover its long-term debt of 77.78 million SEK, raising concerns about its ability to meet long-term obligations. Profitability metrics are deeply negative, with a return on equity of -239.63% and a return on assets of -26.9%. These figures are well below the typical performance of the specialty chemicals industry, which generally expects positive returns on invested capital. The company reported a net loss of 36.37 million SEK and an operating loss of 31.57 million SEK, indicating a failure to generate sustainable earnings. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks and limits the company's ability to offset losses in one area with gains in another. Growth prospects are uncertain, with the company reporting a revenue of 106.19 million SEK in the latest period. Analysts have estimated a modest increase to 113.00 million SEK, but the company's operating and net losses suggest that any growth is not yet translating into profitability. The negative operating cash flow of -8.29 million SEK and free cash flow of -30.29 million SEK further indicate that the company is not generating sufficient cash to sustain operations or fund growth. The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with the company's net cash position being negative after subtracting total debt. The dilution risk is rated as low, but the company's negative earnings and cash flow may necessitate future equity raises, which could dilute existing shareholders. Recent financial filings and transcripts indicate that the company is operating in a challenging market environment. The company's negative earnings and cash flow, combined with high debt levels, suggest that it is under pressure to improve its financial performance. No recent major events or strategic announcements have been disclosed that would indicate a clear path to profitability or growth.
Key takeaways
  • OrganoClick is highly leveraged with a debt-to-equity ratio of 5.12, indicating significant financial risk.
  • The company reported a net loss of 36.37 million SEK and an operating loss of 31.57 million SEK, with no signs of profitability.
  • Liquidity is weak, with a current ratio of 0.45 and negative free cash flow of -30.29 million SEK.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • Analysts expect modest revenue growth, but the company's negative cash flow and earnings suggest that any growth is not yet translating into profitability.
  • The company's financial position raises concerns about its ability to meet long-term obligations and sustain operations.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$106.2M
Gross profit$14.9M
Operating income-$31.6M
Net income-$36.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$8.3M
CapEx-$11.0M
Free cash flow-$30.3M
Total assets$135.2M
Total liabilities$120.0M
Total equity$15.2M
Cash & equivalents$2.7M
Long-term debt$77.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$15.2M
Net cash-$75.1M
Current ratio0.5
Debt/Equity5.1
ROA-26.9%
ROE-2.4%
Cash conversion23.0%
CapEx/Revenue-10.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricORGCActivity
Op margin-29.7%5.5% medp25 -0.0% · p75 10.8%bottom quartile
Net margin-34.3%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin14.0%20.5% medp25 12.4% · p75 29.7%below median
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-10.3%-6.2% medp25 -13.4% · p75 -2.6%below median
Debt / equity512.0%37.1% medp25 10.3% · p75 82.0%top quartile
Observations
IR observations
Mean EPS estimate-0.13 SEK
Last actual EPS-0.36 SEK
Mean revenue estimate113,000,000 SEK
Last actual revenue106,190,000 SEK
Mean EBIT estimate-8,000,000 SEK
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 22:00 UTC#c81d51ea
Market quoteclose SEK 0.82 · shares 0.11B diluted
no public URL
2026-05-05 02:40 UTC#902548c9
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 21:15 UTCJob: 299471cd